TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company. The Company is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Vori, TFF Tac-Lac and Triple Combination For chronic obstructive pulmonary disease (COPD)/Asthma. It is developing TFF Vori for the treatment of invasive pulmonary aspergillosis (IPA). TFF Vori is being developed as an inhaled dry powder drug. It is developing TFF Tac-Lac for Immunosuppression to prevent organ transplant rejection. TFF Tac-Lac is being developed as a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. It is also developing a combination dry powder drug intended for use with a dry powder inhaler for the maintenance treatment of bronchospasm associated with moderate to severe COPD.